U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06864182) titled 'Relative Bioavailability Study of CX2101A for the Treatment of COVID-19' on Feb. 24.
Brief Summary: The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and enteric-coated tablets; and a multiple ascending dose (MAD) study of CX2101A tablets. The BA study (100 mg) is integrated into the SAD study(Nested within the SAD protocol to optimize resource utilization).
Study Start Date: March 21, 2024
Study Type: INTERVENTIONAL
Condition:
COVID-19
Coronavirus Infection
Int...